Skip to main content
Philogen logo

Philogen — Investor Relations & Filings

Ticker · PHIL ISIN · IT0005373789 LEI · 81560009EA1577917768 XMIL Manufacturing
Open in API
Filings indexed 377 across all filing types
Latest filing 2021-11-24 Transaction in Own Shar…
Country IT Italy
Listing XMIL PHIL

About Philogen

https://www.philogen.com

Philogen is a clinical-stage biotechnology company focused on the discovery and development of novel biopharmaceutical products for the treatment of cancer and other serious conditions associated with angiogenesis. Founded in 1996, the company's core strategy is based on innovating targeted therapies, such as antibody-cytokine fusions, which are designed to selectively deliver therapeutic agents to the site of disease. This approach aims to increase efficacy while reducing toxicity. Philogen operates as an integrated company with capabilities in research, GMP manufacturing, and clinical development of its proprietary product pipeline.

Recent filings

Filing Released Lang Actions
Comunicato Stampa - L’Assemblea degli Azionisti autorizza l’acquisto e la disposizione di azioni proprie ed il Consiglio di Amministrazione approva l’avvio del programma (Price sensitive)
Transaction in Own Shares Classification · 98% confidence The document text explicitly details the resolutions passed during an 'Assemblea degli Azionisti' (Shareholders' Meeting). Key resolutions include authorizing the purchase and disposal of own shares ('acquisto e la disposizione di azioni proprie') and the subsequent approval by the Board of Directors to start the share buyback program ('Programma di acquisto di azioni proprie'). Furthermore, it mentions that the minutes of the Assembly ('verbale dell'Assemblea') and the summary of voting results ('rendiconto sintetico delle votazioni') will be made available, referencing Italian regulations (TUF, Consob). This content strongly aligns with the documentation surrounding an Annual General Meeting (AGM) where such authorizations are typically granted, and the subsequent announcement of voting outcomes. Since the document focuses on the decisions made at the meeting itself, 'AGM-R' (AGM Information) is the most appropriate classification, as it covers presentations and materials shared during the AGM.
2021-11-24 Italian
Comunicazione Internal Dealing
Director's Dealing Classification · 100% confidence The document text is in Italian and contains structured tables detailing transactions ('Operazioni Rilevanti') involving shares of Philogen S.p.A. It specifically mentions 'Dati relativi al Soggetto Obbligato dello Notifica' (Data relating to the Obligated Subject of the Notification), 'Posizione/qualifica' (Position/qualification) as 'Consigliere' (Director), and includes sections for 'Notifica iniziale/modifica' (Initial/modification notification) and 'Dichiarazione resa dal Soggetto Rilevante' (Declaration made by the Relevant Subject). The content clearly relates to insider trading reports, specifically transactions conducted by a director (Sergio Gianfranco Luigi Maria Dompé) in the company's shares, which falls under the category of Director's Dealing reports. This aligns perfectly with the definition for Director's Dealing (Code: DIRS).
2021-11-22 Italian
Comunicazione internal dealing
Director's Dealing Classification · 99% confidence The document is titled "Modello di notifica e di comunicazione al pubblico delle Operazioni Rilevanti da parte dei Soggetti Rilevanti Interni" (Notification and public disclosure model for Relevant Transactions by Inside Persons) and contains detailed tables outlining a transaction ('Acquisto di azioni sul mercato' - Purchase of shares on the market) by an individual ('Sergio Gianfranco Luigi Maria Dompé') who holds the position of 'Consigliere di Philogen S.p.A.' (Director of Philogen S.p.A.). It also includes declarations regarding control over various legal entities and personal data consent related to 'Internal Dealing'. This structure is characteristic of mandatory disclosures concerning insider trading or transactions by directors/managers, which falls under the category of Director's Dealing (DIRS) or potentially a specific regulatory filing (RNS). Given the explicit focus on transactions by a director/insider, 'DIRS' (Director's Dealing) is the most precise classification, as it directly relates to reporting personal share transactions by company directors and executives.
2021-11-19 Italian
COMUNICAZIONE AI SENSI DELL’ART. 85-BIS, COMMA 4-BIS, DEL REGOLAMENTO EMITTENTI
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is titled "COMUNICAZIONE AI SENSI DELL'ART. 85-BIS, COMMA 4-BIS, DEL REGOLAMENTO EMITTENTI" and is dated November 16, 2021, in preparation for a shareholder meeting on November 24, 2021. The core content is a table detailing the total number of shares and the total voting rights, as required by Italian regulatory body Consob (Delibera n. 11971). This specific disclosure relates to the capital structure and voting rights ahead of a general meeting. This aligns perfectly with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), which covers official results or preparatory announcements regarding shareholder votes at general meetings. Although it mentions the upcoming 'Assemblea degli Azionisti' (Shareholder Meeting), the primary purpose of this specific communication is the mandatory disclosure of voting rights structure.
2021-11-16 Italian
Press Release - THE BOARD OF DIRECTORS APPROVES THE POSITIVE NET FINANCIAL POSITION FOR THE THIRD QUARTER OF 2021 AND AND NOTES THE PROGRESS OF THE MAIN TRIALS
Earnings Release Classification · 98% confidence The document is a press release dated November 11, 2021, announcing the approval of the Group's net financial position as of September 30, 2021 (Q3 2021). It includes a detailed table showing key financial metrics (Liquidity, Net Financial Debt) compared across several quarters/year-end dates (Q3 2021, Q2 2021, Q1 2021, FY 2020). It also provides updates on clinical trials and includes a declaration by the manager responsible for preparing the financial reports. This content structure—financial highlights for a specific interim period, management commentary, and regulatory compliance statements—is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it focuses heavily on the financial position update for the third quarter and includes management commentary on results, it aligns best with an Earnings Release (ER), which is the initial announcement of periodical financial results (key highlights). It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR) which usually contains full IFRS statements, but rather the press release summarizing those results. 9M 2021
2021-11-11 English
Comunicato stampa_IL CONSIGLIO DI AMMINISTRAZIONE APPROVA LA POSIZIONE FINANZIARIA NETTA RELATIVA AL TERZO TRIMESTRE 2021 E E PRENDE ATTO DELLO STATO DI AVANZAMENTO DEI TRIALS PRINCIPALI
Earnings Release Classification · 95% confidence The document is a press release from Philogen S.p.A. announcing its net financial position for the third quarter of 2021 and providing an update on clinical trial progress. It contains specific financial data (net financial position table) and management commentary. While it provides financial data, it is a periodic update rather than a full comprehensive quarterly report (which would be a formal 10-Q or equivalent). In the context of financial reporting, this type of announcement is classified as an Earnings Release (ER) as it provides key financial highlights and business updates for a specific period. 9M 2021
2021-11-11 Italian

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.